Cartesian Therapeutics (RNAC) Intangibles (2023 - 2026)

Cartesian Therapeutics (RNAC) has reported Intangibles for 4 consecutive years, with $93.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Intangibles fell 37.65% year-over-year to $93.9 million; the TTM figure through Mar 2026 stood at $93.9 million (down 37.65% YoY), while the FY2025 annual figure was $93.9 million, down 37.65% from the prior year.
• Intangibles steadied at $93.9 million in Q1 2026 per RNAC's latest filing, from $93.9 million in the prior quarter.
• Across five years, Intangibles topped out at $150.6 million in Q4 2023 and bottomed at $93.9 million in Q4 2025.
• Historically, Intangibles has averaged $139.3 million across 4 years, with a median of $150.6 million in 2023.
• Annual changes were most pronounced in 2024 — Intangibles changed 0.0% — and 2025, when it tumbled 37.65%.
• Cartesian Therapeutics' Intangibles stood at $150.6 million in 2023, then changed by 0.0% to $150.6 million in 2024, then sank by 37.65% to $93.9 million in 2025, then changed by 0.0% to $93.9 million in 2026.
• Business Quant data shows RNAC's Intangibles at $93.9 million in Q1 2026, $93.9 million in Q4 2025, and $150.6 million in Q3 2025.